Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

182
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
182
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

310
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
310
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

371
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
371
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

279
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
279
Antiepileptic Drugs: Sodium Channel Blockers01:08

Antiepileptic Drugs: Sodium Channel Blockers

480
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
480
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

158
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
158

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Seletracetam Revisited: A Missed Opportunity for Effective Epilepsy Therapy.

CNS drugs·2026
Same author

Postmortem MRI reveals distinct structural features in sudden unexpected death in epilepsy.

Epilepsia open·2026
Same author

A consensus roadmap for post-traumatic epilepsy: Clinical biomarkers, research priorities, policy barriers, and pathways to interventional trials.

Epilepsia·2026
Same author

The Discovery of Cenobamate: A Drug with High Efficacy in Drug-Resistant Epilepsy.

CNS drugs·2026
Same author

The Complexity and Challenges of Developing Effective Epilepsy Therapies: Lessons to be Learned from Comparing Cenobamate, Carisbamate, and Padsevonil.

CNS drugs·2026
Same author

Ranking of antiseizure medications in a panel of focal seizure models predicts their comparative efficacy in clinical add-on trials in drug-resistant focal epilepsy.

Epilepsia·2026
Same journal

HuR degrader knocks down BRAF in cancer.

Nature reviews. Drug discovery·2026
Same journal

R&D productivity trends for biopharma companies in Asia and emerging markets.

Nature reviews. Drug discovery·2026
Same journal

Growth in clinical research capability in China and impact on the pharmaceutical sector.

Nature reviews. Drug discovery·2026
Same journal

Circular RNA guides exon skipping in DMD.

Nature reviews. Drug discovery·2026
Same journal

p38α inhibition restores axonal transport.

Nature reviews. Drug discovery·2026
Same journal

Inflammatory bowel disease-on-a-chip.

Nature reviews. Drug discovery·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K

New epilepsy therapies in development.

Pavel Klein1, Rafal M Kaminski2, Matthias Koepp3

  • 1Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, USA. kleinp@epilepsydc.com.

Nature Reviews. Drug Discovery
|July 22, 2024
PubMed
Summary
This summary is machine-generated.

Epilepsy, a common brain disorder, lacks preventive treatments and effective control for 30% of patients. Recent advancements offer over 200 novel therapies targeting specific epilepsy mechanisms and prevention strategies.

More Related Videos

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

8.9K
Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease
06:55

Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease

Published on: November 21, 2024

722

Related Experiment Videos

Last Updated: Jun 20, 2025

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

9.0K
Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue
06:45

Generation and On-Demand Initiation of Acute Ictal Activity in Rodent and Human Tissue

Published on: January 19, 2019

8.9K
Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease
06:55

Author Spotlight: Unraveling Neural Communication and Circuit Interactions in Health and Disease

Published on: November 21, 2024

722

Area of Science:

  • Neurology
  • Neuroscience
  • Pharmacology

Background:

  • Epilepsy is a prevalent neurological disorder characterized by recurrent seizures, often accompanied by cognitive and psychiatric issues, and increased mortality.
  • Current antiseizure medications (ASMs) are ineffective in at least 30% of epilepsy patients, and preventive interventions are unavailable.
  • Significant progress in epilepsy genetics, disease models, and drug screening has spurred the development of novel therapeutic approaches.

Purpose of the Study:

  • To review recent advancements in antiseizure medication (ASM) development for epilepsy.
  • To outline future directions for novel therapies aimed at treating and preventing epilepsy.
  • To highlight the shift towards mechanism-based treatments and disease prevention strategies.

Main Methods:

  • Review of recent scientific literature on epilepsy research and therapeutic development.
  • Analysis of preclinical and clinical pipelines for novel epilepsy therapies.
  • Assessment of progress in diagnostic and predictive biomarkers for epilepsy.

Main Results:

  • Over 200 novel epilepsy therapies are in development, targeting diverse mechanisms.
  • Emerging therapies include treatments for epilepsy prevention and mechanism-based interventions.
  • Diagnostic and predictive biomarkers are facilitating personalized epilepsy treatment.

Conclusions:

  • The field of epilepsy treatment is transitioning from symptom management to disease modification and prevention.
  • Innovative therapies and biomarkers are paving the way for more effective and personalized epilepsy care.
  • Future research should focus on developing targeted therapies and preventive strategies for specific epilepsy syndromes.